As the pipelines of their pharmaceutical and biotech clients continue to yield new drugs for patients, agencies are also seeing their business grow.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
2017 was a very good year for many of the agencies profiled in this annual directory featuring the leading healthcare communications agencies. Some reported individual setbacks, but they were still able to overcome these. As a wave of new drugs and biologics hit the market, several of the top healthcare agencies supported their launches.
Biologic medicines and immunotherapy are front and center amongst many of the R&D strategies and platforms for the industry’s leading developers.
The industry’s patent cliffs have become less steep, but the Affordable Care Act will give pharma new challenges.
Fluidity was the state of pharmaceutical advertising in 2013, as agencies shifted their operations, personnel, and tactics to meet the needs of their clients, driven by the pace of digital.
The worldwide drug-delivery arena is growing each year as the increasing aging population is in need of improved methods of administration for products and therapies.
From big pharma to smaller specialty entities, contract manufacturing serves as a strategy for various industry players.
The global market for consumer-care products generated slower growth in 2010 than during the previous year, partially because of a weaker flu season in North America and Europe.